Skip to content
On Feb. 28, 2023, the U.S. Food and Drug Administration (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommended approval for Pfizer’s respiratory […]
FDA’s advisory panel backs GSK’s RSV vaccine Read More »
The Pfizer RSV vaccine candidate for adults over 60 has been recommended by an advisory committee of the Food and Drug Administration (FDA), and
FDA panel recommends Pfizer RSV vaccine for older adults Read More »
Pain is the number one reason most Americans go to the doctor is pain, says Cindy Steinberg, Director of Policy and Advocacy for the
Can biotech crack the code on pain medications? Read More »
For three decades, Genethon, a non-profit research organization, has pioneered development of gene therapies for rare and ultra-rare diseases. Now that our hard work
A significant increase in the percentage of Shigella infections caused by extensively drug-resistant (XDR) versions of the bacteria has prompted the U.S. Centers for
The rise of drug-resistant Shigella offers glimpse into danger AMR poses Read More »
According to a recent report from IQVIA, the market for biosimilars, which mimic innovative biologics, is poised to grow this year. Since 2007, a
Biosimilars expected to boom in 2023-27, says report Read More »
Starting Veklury (remdesivir) within the first two days of hospitalization for COVID-19 can reduce mortality and decrease readmission rates for all hospitalized patients, regardless
Gilead’s anti-COVID Veklury reduces risk of death Read More »
Pfizer’s vaccine aimed at protecting infants against severe respiratory syncytial virus (RSV) could roll out as early as this summer as the Food and
Pfizer’s RSV vaccine for infants could be approved this summer Read More »
“You know,” Karyne Jones laughs, “I am about the same age as many of the people I work with, so the older I get,
NCBA understands that, in Black America, health care is holistic Read More »
When it comes to long COVID, health care providers and the biotech industry must be aware of what is already known, but we still
BIO’s long COVID webinar furthers search for biotech solutions Read More »
